Pivotal trial results for guselkumab (Tremfya) in patients with active psoriatic arthritis were published on 2020-01-01. The DISCOVER-1 study evaluated the efficacy and safety of guselkumab in both biologic-naive patients and those previously treated with TNFα inhibitors.
Background
Guselkumab was evaluated for the treatment of active psoriatic arthritis. Psoriatic arthritis is a chronic inflammatory disease characterized by joint inflammation, enthesitis, dactylitis, and often associated with psoriasis. It can significantly impact a patient's quality of life and functional ability.
Trial design
The DISCOVER-1 study was a double-blind pivotal trial. It investigated guselkumab in participants with active psoriatic arthritis, including those who were biologic-naive or had previously received TNFα inhibitor treatment.
What this means
The publication of the DISCOVER-1 study results on 2020-01-01 makes the efficacy and safety data for guselkumab in active psoriatic arthritis publicly accessible. This includes data from both biologic-naive patients and those previously treated with TNFα inhibitors, a population where treatment options can be critical. The availability of these pivotal trial findings allows clinicians, researchers, and patient advocates to thoroughly review the evidence supporting guselkumab as a potential treatment option for this chronic inflammatory condition. It contributes to the growing body of knowledge on therapeutic approaches for psoriatic arthritis.
Source
The information regarding the DISCOVER-1 study was published on 2020-01-01. The details are available via PubMed, referencing a publication in The Lancet, at pubmed.ncbi.nlm.nih.gov.